CENTRALPHL

Central Pharmaceuticals Limited · Pharmaceuticals and Chemicals · Cat Z

0/100

High risk

৳10.8

DSE Hexagon

Stands out for constructive price action, held back by little dividend.

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (3)

⚠ Z-category — higher default/governance risk
⚠ Signs of concentrated-operator price activity
⚠ Dividend sustainability at risk

Rewards (1)

✓ Earnings trending up

Score breakdown

Price history & performance

52-week high৳12.1

52-week low৳7.80

From 52w high-10.7%

Beta1.14

7D +4.9%

1M +20.0%

3M +14.9%

6M +27.1%

1Y +6.9%

YTD +20.0%

Shareholder returns vs DSEX

CENTRALPHL+2.9%

DSEX+2.4%

CENTRALPHL outperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility53.5%

Daily VaR (95%)-4.6%

Max drawdown (5y)-76.6%

Correlation to market0.57

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)65.9

MACDbullish

Bollingerinside bands (+1.4σ)

Price cycle (Wyckoff)MARKUP

Health trendstable

Flow pressureaccumulation

Valuation

Fair value ()

Upside—

Dividend yield+0.00%

Fundamental verdictAT-RISK

Confidence—

Ownership

Institutional holding13.57%

Foreign holding0.0%

Free float78.76%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳3,000mn

Paid-up capital৳1,198.01mn

Face value৳10

Market lot1

Outstanding shares119,800,844

Last AGM30-12-2025

Fiscal year end30-Jun

Reserve & surplus (ex-OCI)৳-374.7mn

Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E

Jul 14, 2026 — —

Jul 13, 2026 — —

Jul 12, 2026 — —

Jul 9, 2026 — —

Jul 8, 2026 — —

Jul 7, 2026 — —

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

20191%

Earnings & NAV

YearEPSNAVDividend

2025 -0.18 6.87 0%

2024 -0.35 7.06 0%

2023 -0.37 5.59 0%

2022 -0.57 5.96 0%

Quarterly EPS — FY2026

Q1-0.07

Q2-0.06

Half-year-0.14

Q3-0.09

Nine-month-0.23

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳10.9

৳11.4

৳12

৳12.4

Support

৳10.4

৳10

৳9.7

৳9.3

Historical bounce zones

Jun 23, 2025: ৳9.3→৳12.7 +37%

Aug 24, 2025: ৳9.7→৳11.2 +15%

Nov 4, 2025: ৳7.9→৳9.7 +23%

Nov 16, 2025: ৳7.1→৳10.2 +44%

Jan 15, 2026: ৳8→৳9.7 +21%

Mar 8, 2026: ৳8.1→৳10 +23%

May 12, 2026: ৳8.2→৳9.7 +18%

Jun 22, 2026: ৳8.9→৳11.4 +28%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

ScripScorePriceUpsideYield

IBNSINAThe IBN SINA Pharmaceutical Industry PLC 87 ৳326.5 +12.00% +2.00%MARICOMarico Bangladesh Limited 87 ৳2,732.4 +24.00% +2.20%SQURPHARMASquare Pharmaceuticals PLC. 85 ৳221.4 +120.00% +5.40%ACMELABThe ACME Laboratories Limited 79 ৳86.9 +138.00% +4.10%BXPHARMABeximco Pharmaceuticals PLC. 78 ৳153.2 +54.00% +2.60%RENATARenata PLC 64 ৳464.3 -25.00% +1.20%

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 32% vs 40% market avg Typical move: -6.2% / -1.3% / 5.5%

30-day 41% vs 42% market avg Typical move: -10.4% / -2.4% / 8.7%

Signals: RSI>70 overbought|Above upper Bollinger|Stochastic>80

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readAVOID (dormant/dirty)

Reference stopn/a

Reference target—

Timing notestay out

strong artificial activity (score 435); speculative profile — not core-quality. Phase: DORMANT (19% >200-MA, flow ACC) -> watch. Elevated sharp-fall risk 13%. Z-cat. ⚠ SOLVENCY DISTRESS (Altman Z -1.05, STABLE) — bankruptcy risk. high-risk. [fundamentals AT-RISK (dividend cut risk), yield 0.0%]